search button
Open Access

Efficacy and safety of different doses of evolocumab in reducing low-density lipoprotein cholesterol levels: A meta-analysis

  • Authors:
    • Cheng Cheng
    • Sijia Sun
    • Yafeng Zhou
    • Xiangjun Yang

  • View Affiliations

  • Published online on: September 29, 2016     https://doi.org/10.3892/br.2016.766
  • Pages: 541-547

  • Copyright: © Cheng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Evolocumab has been considered as an efficacious, safe and promising therapeutic modality for hyperchol­esterolemia and is associated with cardiovascular diseases. The efficacy and safety of two different doses of evolocumab were evaluated and the safety of evolocumab was compared with that of a placebo and ezetimibe. PubMed and EMBASE databases were searched and randomized controlled trials that examined the effect and safety of evolomucab compared with a placebo and ezetimibe were retrieved. Two authors independently performed article reviews and study quality evaluations. Odds ratios (ORs) were calculated using a fixed or random‑effects model [95% confidence intervals (CIs)]. In the direct comparison, a significant reduction was observed in the muscle‑associated events compared with ezetimibe [OR=0.54 (95% CI, 0.31‑0.93); P (Z)=0.03, P (Q)=0.43, I2=0%]. In the adjusted indirect comparison of evolocumab 140 mg Q2W vs. evolocumab 420 mg Q4W, no significant differences in efficacy [OR=1.04 (95% CI, 0.55‑1.99); P (Z)=0.90] or adverse events [OR=1.08 (95% CI, 0.66‑1.74); P (Z)=0.76] were identified. The funnel plots of these direct comparison studies indicated that there was no publication bias. The results of this meta‑analysis demonstrate that evolocumab significantly reduced low‑density lipoprotein cholesterol levels, and no difference was noted between evolocumab 140 mg Q2W and evolocumab 420 mg Q4W. Furthermore, evolocumab had fewer muscle‑associated events than ezetimibe.
View Figures
View References

Related Articles

Journal Cover

November-2016
Volume 5 Issue 5

Print ISSN: 2049-9434
Online ISSN:2049-9442

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.3
  • Ranked
    (total number of cites)
  • CiteScore: 3.7
  • CiteScore Rank: Q2: #23/79 Pharmacology, Toxicology and Pharmaceutics
  • Source Normalized Impact per Paper (SNIP): 0.742
  • SCImago Journal Rank (SJR): 0.488
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Cheng C, Sun S, Zhou Y and Yang X: Efficacy and safety of different doses of evolocumab in reducing low-density lipoprotein cholesterol levels: A meta-analysis. Biomed Rep 5: 541-547, 2016
APA
Cheng, C., Sun, S., Zhou, Y., & Yang, X. (2016). Efficacy and safety of different doses of evolocumab in reducing low-density lipoprotein cholesterol levels: A meta-analysis. Biomedical Reports, 5, 541-547. https://doi.org/10.3892/br.2016.766
MLA
Cheng, C., Sun, S., Zhou, Y., Yang, X."Efficacy and safety of different doses of evolocumab in reducing low-density lipoprotein cholesterol levels: A meta-analysis". Biomedical Reports 5.5 (2016): 541-547.
Chicago
Cheng, C., Sun, S., Zhou, Y., Yang, X."Efficacy and safety of different doses of evolocumab in reducing low-density lipoprotein cholesterol levels: A meta-analysis". Biomedical Reports 5, no. 5 (2016): 541-547. https://doi.org/10.3892/br.2016.766